Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Therapeutic treatment for lung conditions

A technology of pulmonary hypertension and its precursors, which can be applied to respiratory diseases, cardiovascular diseases, medical preparations containing active ingredients, etc., and can solve problems such as death and right-sided heart failure

Inactive Publication Date: 2011-02-09
VANDERBILT UNIV
View PDF6 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Ultimately, chronic hypoxia leads to severe pulmonary hypertension, which eventually leads to right-sided heart failure and death

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Therapeutic treatment for lung conditions
  • Therapeutic treatment for lung conditions
  • Therapeutic treatment for lung conditions

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1-4

[0056] The following example evaluates whether oral supplementation with L-citrulline prevents the development of pulmonary hypertension and the consequent decrease in NO production during exposure of neonatal piglets to chronic hypoxia for 10 days.

[0057] The method used in Examples 1-4

[0058] animal care

[0059] A total of 17 hypoxic and 17 control piglets were studied. see figure 2 . Twelve-day-old control animals were studied on the day of arrival from the farm. Hypoxic pigs (2 days old) were placed in a hypoxic chamber at atmospheric pressure for 10-11 days. Atmospheric hypoxia was provided using compressed air and nitrogen to produce 8-11% inspired oxygen (PO 2 60-72Torr), and the CO is absorbed by soda lime 2 Keep it at 3-6Torr. Animals' daily body weight was monitored and physical examination was performed twice daily. They were bred ad libitum with pig milk substitute in a cage feeding facility.

[0060] L-Citrulline Supplement

[0061] Oral supplemen...

Embodiment 1

[0080] In vivo hemodynamic measurements

[0081] On the study day in 12-13 day old animals, both L-citrulline-treated and untreated hypoxic animals had lower cardiac output and weight compared to age-matched control piglets and higher LVEDP measurements (Table 1). Measurements of aortic pressure and blood gas indices were similar in the cohort (paO in control piglets 2 74 ± 5 ​​Torr, paO in untreated hypoxic piglets 2 74±8 Torr, paO in hypoxic piglets treated with L-citrulline 2 78±7 Torr; paCO2 in control piglets was 39±2, paCO2 in untreated hypoxic piglets was 41±4, and paCO2 in hypoxic piglets treated with L-citrulline was 30±1.0 ). obviously, as image 3 As shown, hypoxic animals treated with L-citrulline had significantly lower pulmonary arterial pressure compared to untreated hypoxic animals (p-value 0.01). Pulmonary arterial pressure did not differ between normoxic control animals and hypoxic animals treated with L-citrulline (p=0.08).

[0082] Additionally, if ...

Embodiment 2

[0084] exhaled NO output and perfusate NO x -

[0085] Such as Figure 5 As shown, exhaled NO output was higher in control animals and hypoxic animals treated with L-citrulline than in untreated hypoxic animals (p-values ​​0.001 and 0.032, respectively). However, there was no difference in exhaled NO output between control animals and hypoxic animals treated with L-citrulline (p=0.124).

[0086] Such as Image 6 As shown, lungs of control animals (p=0.02) and L-citrulline-treated hypoxic animals (p=0.04) had significantly higher NOx compared to lungs of untreated hypoxic animals - accumulation rate. Moreover, NOx in the lungs of hypoxic animals treated with L-citrulline compared - There was no difference in the rate of accumulation.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Methods and compositions for treating lung conditions such as bronchopulmonary dysplasia or hypoxia-induced pulmonary hypertension in a subject, including administering to the subject an effective amount of a nitric oxide precursor such as citrulline.

Description

[0001] Related application information [0002] This patent application is based on, and claims priority from, US Provisional Patent Application Serial No. 61 / 025,157, filed January 31, 2008, which is hereby incorporated by reference in its entirety. technical field [0003] The present invention relates to the treatment of pulmonary disorders such as, for example, bronchopulmonary dysplasia (BPD) and chronic hypoxia-induced pulmonary hypertension in infants. Background of the invention [0004] Bronchopulmonary dysplasia (BPD) commonly occurs in infants, especially preterm infants, and is characterized by acute injury to the lungs by oxygen and / or mechanical ventilation, which results in disturbance or suppression of alveolar and vascular development (Jobe et al. 2001) Am J Respir Crit Care Med 163:1723-1729). In animal models, inhaled NO promotes gas exchange and lung structural development, but the use of this therapy in infants at risk for BPD is controversial (Ballard ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/00A61P11/00
CPCA61K31/198A61P9/12A61P11/00A61K9/0019A61K9/08A61K9/10
Inventor 马歇尔·L.·萨默弗雷德里克·E.·巴尔C·D·菲克J·L·阿施纳
Owner VANDERBILT UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com